Brief: Ipsen SA Says Cabometyx Approved In EU For Previously Treated Advanced Neuroendocrine Tumors
24/07/2025 19:25
July 24 (Reuters) - Ipsen SA IPN.PA: IPSEN SA: CABOMETYX APPROVED IN EU FOR PREVIOUSLY TREATED ADVANCED NEUROENDOCRINE TUMORS Source text: ID:nGNX51Jvlm Further company coverage: IPN.PA (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients